←
Melissa L. Johnson567 posts
Melissa L. Johnson avatar✓

Melissa L. Johnson ✓

@MLJohnsonMD2

Medical oncologist whose focus is drug development for lung cancer patients being treated in the community.

◷ Joined October 2015▧ 65 Photos and videos
Herbert Loong, MBBS, FASCO avatar
⟳ Melissa L. Johnson retweeted
Herbert Loong, MBBS, FASCO@herbloong·Apr 10

Lots of work to be done today as #trackchairs under leadership of the congress chairs @MLJohnsonMD2 and @tompowles1 of @myESMO #ESMO27 get together to confirm the educational sessions for the meeting - more than 1.5 years in advance. 24+ tracks at upcoming #ESMO27 in Barcelona. Stay tuned! @FAndreMD @curijoey @LizzySmyth1 @GPentheroudakis @AACRPres @MartinReck2 @ca_chung @NReguart @hoperugo #MakotoTahara @TeresaSAmaral and many others

Post attachmentPost attachmentPost attachmentPost attachment
ASCO avatar
⟳ Melissa L. Johnson retweeted
ASCO@ASCO·6 Feb 2025

Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more: brnw.ch/21wQwer

Post attachment
Elisabeth Potter MD avatar
⟳ Melissa L. Johnson retweeted
Elisabeth Potter MD@EPotterMD·9 Feb 2025

On January 7th, 2025 I shared a video, after I was asked to call UnitedHealthcare from the operating room to answer administrative questions about the patient who was having surgery to treat breast cancer. Despite my efforts, they denied her stay. UnitedHealthcare didn’t stop at calling me during surgery. Now, they’ve sent me a legal threat—and even worse? They ended up denying my cancer patient’s hospital stay. Exactly what I was afraid would happen. Staying overnight after major surgery isn’t optional—it’s medically necessary. But UnitedHealthcare decided they know better than the doctors caring for the patient. When they called me while I was operating, I knew that if I didn’t step out and respond immediately, they might deny her stay—leaving her with a massive bill. So, with another surgeon in the OR, I scrubbed out and called them back. But after all of that? They denied her stay anyway. And instead of fixing their broken system, they sent me a legal threat for speaking out. I’m sharing their response in full, letting their words speak for themselves. Let me be clear: I stand by everything I said. I told the truth. I was honest about what’s happening in our healthcare system. And I will not be silenced by legal threats when it comes to advocating for my patients and my ability to care for them. Denying an overnight stay that a doctor orders is dangerous. The doctor caring for the patient should be able to make these decisions without delay, pressure, or harassment. If I don’t speak up, I lose—my integrity, my voice, and the opportunity to make a difference. And while it’s intimidating to receive a letter like this from a company as powerful as UnitedHealthcare, I know where I stand. I am a woman taking care of women affected by breast cancer. I do this work with all of my heart, and I will continue to speak up for my patients—because they deserve better. I ask you to follow along, share this story, and have these conversations in your own communities. I know I’m not the only one dealing with this, and real change will take all of us telling our stories and standing up for what’s right. I’m here for it. Are you?

1:26
Clay Stauffer avatar
⟳ Melissa L. Johnson retweeted
Clay Stauffer@PreacherClay·6 Oct 2024

Goal post in the Cumberland!!

0:20
RobynsResistance247💙🇺🇸 avatar
⟳ Melissa L. Johnson retweeted
RobynsResistance247💙🇺🇸@RobynEvansinCal·16 Sep 2024

I agree he is pure evil 👿 your wife is a very smart woman. Smart women will help lead this Country out of chaos, hate & division to keep our Democracy alive & well.

JessicaJLinMD avatar
⟳ Melissa L. Johnson retweeted
JessicaJLinMD@JessicaJLinMD·13 Sep 2024

We are pleased to share this article out today in @CD_AACR on the preclinical development and proof-of-concept clinical activity of NVL-655 ✅4th-generation, #ALK-selective TKI ✅CNS-penetrant ✅Broad coverage of ALK fusions and mutations, including lorlatinib-refractory compound mutations 🔥Fills an important unmet need for pts with ALK+ lung cancer and other solid tumors 📢Tune in for updated prelim efficacy&safety data from the global ongoing phase I/II study (ALKOVE-1) of NVL-655 to be presented TOMORROW at #ESMO2024! @ALKPositiveinc @ALKpositiveINT @MGHCancerCenter @MassGeneralNews @alexdrilon @MSKCancerCenter @BenjaminBesseMD @MLJohnsonMD2 @DRCamidge @jii_bum_lee @ViolaWZhu aacrjournals.org/cancerdisco…

Post attachment
Mary Jo Fidler avatar
⟳ Melissa L. Johnson retweeted
Mary Jo Fidler@maryjofidlerMD·7 Sep 2024

WCLC off to a great start! Dr Rudin presents IDxd in extensive stage small cell. High disease control with higher dose, predominantly GI tox #wclc24

Post attachmentPost attachment